Skip to main content
Top
Published in: Rheumatology International 11/2014

01-11-2014 | Review Article

Growth abnormalities in children and adolescents with juvenile idiopathic arthritis

Authors: Susanne Bechtold, Dominique Simon

Published in: Rheumatology International | Issue 11/2014

Login to get access

Abstract

In patients with juvenile idiopathic arthritis (JIA) growth impairment and variance in body composition are well-known long-term complications. In the active phases of the disease, particular patients with systemic and polyarticular JIA reveal growth impairment. Some experience “catch-up” growth following reduction in disease activity and lower glucocorticoid doses. Although new therapeutic options are available, there are still 10–20 % of patients with severe forms of the disease who show continuous growth disturbance. Only few studies have specifically addressed body composition in JIA. Bone mass deficits in part could be related to the deficits of muscle mass. Study data on growth hormone treatment in short children with JIA are promising in respect of growth development, final height and body composition. The major goal for physicians is optimal disease control while maintaining normal growth and body composition. Early recognition of patients who develop prolonged growth and body composition disturbances is important as these abnormalities contribute to long-term morbidity and need to be addressed both diagnostically and therapeutically.
Literature
1.
go back to reference von Koskull S, Truckenbrodt H, Holle R, Hormann A (2001) Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: a prospective study. Ann Rheum Dis 60:940–945CrossRef von Koskull S, Truckenbrodt H, Holle R, Hormann A (2001) Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: a prospective study. Ann Rheum Dis 60:940–945CrossRef
2.
go back to reference Simon D, Fernando C, Czernichow P, Prieur AM (2002) Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 29:1296–1300PubMed Simon D, Fernando C, Czernichow P, Prieur AM (2002) Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 29:1296–1300PubMed
3.
go back to reference Kotaniemi A (1997) Growth retardation and bone loss as determinants of axial osteopenia in juvenile chronic arthritis. Scand J Rheumatol 26:14–18PubMedCrossRef Kotaniemi A (1997) Growth retardation and bone loss as determinants of axial osteopenia in juvenile chronic arthritis. Scand J Rheumatol 26:14–18PubMedCrossRef
4.
go back to reference Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65:1044–1049PubMedCrossRefPubMedCentral Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65:1044–1049PubMedCrossRefPubMedCentral
5.
go back to reference Liem JJ, Rosenberg AM (2003) Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol 21:663–668PubMed Liem JJ, Rosenberg AM (2003) Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol 21:663–668PubMed
6.
go back to reference Still GF (1897) On a form of chronic joint disease in children. Med Chir Trans 80(47–60):49 Still GF (1897) On a form of chronic joint disease in children. Med Chir Trans 80(47–60):49
8.
go back to reference Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, Schwarz HP (2007) Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 92:3013–3018PubMedCrossRef Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, Schwarz HP (2007) Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 92:3013–3018PubMedCrossRef
9.
go back to reference Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N, Papale MR (1997) Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 26:99–103PubMedCrossRef Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N, Papale MR (1997) Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 26:99–103PubMedCrossRef
10.
go back to reference Bechtold S, Beyerlein A, Ripperger P, Roeb J, Dalla Pozza R, Hafner R, Haas JP, Schmidt H (2012) Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center. Growth Horm IGF Res 22:180–185PubMedCrossRef Bechtold S, Beyerlein A, Ripperger P, Roeb J, Dalla Pozza R, Hafner R, Haas JP, Schmidt H (2012) Total pubertal growth in patients with juvenile idiopathic arthritis treated with growth hormone: analysis of a single center. Growth Horm IGF Res 22:180–185PubMedCrossRef
11.
go back to reference Zak M, Muller J, Karup Pedersen F (1999) Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm Res 52:80–85PubMedCrossRef Zak M, Muller J, Karup Pedersen F (1999) Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm Res 52:80–85PubMedCrossRef
12.
go back to reference Rall LC, Roubenoff R (2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 43:1219–1223PubMedCrossRef Rall LC, Roubenoff R (2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 43:1219–1223PubMedCrossRef
13.
go back to reference Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Hafner R, Schwarz HP (2004) Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 31:1407–1412PubMed Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Hafner R, Schwarz HP (2004) Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 31:1407–1412PubMed
14.
go back to reference Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M (2007) Osteoporosis in juvenile idiopathic arthritis: a practical approach to diagnosis and therapy. Eur J Pediatr 166:775–784PubMedCrossRef Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M (2007) Osteoporosis in juvenile idiopathic arthritis: a practical approach to diagnosis and therapy. Eur J Pediatr 166:775–784PubMedCrossRef
15.
go back to reference Knops N, Wulffraat N, Lodder S, Houwen R, de Meer K (1999) Resting energy expenditure and nutritional status in children with juvenile rheumatoid arthritis. J Rheumatol 26:2039–2043PubMed Knops N, Wulffraat N, Lodder S, Houwen R, de Meer K (1999) Resting energy expenditure and nutritional status in children with juvenile rheumatoid arthritis. J Rheumatol 26:2039–2043PubMed
16.
go back to reference Lofthouse CM, Azad F, Baildam EM, Akobeng AK (2002) Measuring the nutritional status of children with juvenile idiopathic arthritis using the bioelectrical impedance method. Rheumatology 41:1172–1177PubMedCrossRef Lofthouse CM, Azad F, Baildam EM, Akobeng AK (2002) Measuring the nutritional status of children with juvenile idiopathic arthritis using the bioelectrical impedance method. Rheumatology 41:1172–1177PubMedCrossRef
17.
go back to reference Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA (1999) A 6-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res 14:1672–1679PubMedCrossRef Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA (1999) A 6-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res 14:1672–1679PubMedCrossRef
18.
go back to reference Frost HM, Schonau E (2000) The “muscle-bone unit” in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 13:571–590PubMedCrossRef Frost HM, Schonau E (2000) The “muscle-bone unit” in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 13:571–590PubMedCrossRef
19.
go back to reference Burnham JM, Shults J, Sembhi H, Zemel BS, Leonard MB (2006) The dysfunctional muscle-bone unit in juvenile idiopathic arthritis. J Musculoskelet Neuronal Interact 6:351–352PubMed Burnham JM, Shults J, Sembhi H, Zemel BS, Leonard MB (2006) The dysfunctional muscle-bone unit in juvenile idiopathic arthritis. J Musculoskelet Neuronal Interact 6:351–352PubMed
20.
go back to reference Burnham JM, Shults J, Dubner SE, Sembhi H, Zemel BS, Leonard MB (2008) Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. Arthritis Rheum 58:2518–2527PubMedCrossRefPubMedCentral Burnham JM, Shults J, Dubner SE, Sembhi H, Zemel BS, Leonard MB (2008) Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. Arthritis Rheum 58:2518–2527PubMedCrossRefPubMedCentral
21.
go back to reference De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142:4818–4826PubMedCrossRef De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142:4818–4826PubMedCrossRef
22.
go back to reference De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Investig 99:643–650PubMedCrossRefPubMedCentral De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Investig 99:643–650PubMedCrossRefPubMedCentral
23.
go back to reference Bergad PL, Schwarzenberg SJ, Humbert JT, Morrison M, Amarasinghe S, Towle HC, Berry SA (2000) Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 279:C1906–C1917PubMed Bergad PL, Schwarzenberg SJ, Humbert JT, Morrison M, Amarasinghe S, Towle HC, Berry SA (2000) Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 279:C1906–C1917PubMed
24.
go back to reference Thissen JP, Verniers J (1997) Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 138:1078–1084PubMed Thissen JP, Verniers J (1997) Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 138:1078–1084PubMed
25.
go back to reference von Laue S, Ross RJ (2000) Inflammatory cytokines and acquired growth hormone resistance. Growth Horm IGF Res 10(Suppl B):S9–S14CrossRef von Laue S, Ross RJ (2000) Inflammatory cytokines and acquired growth hormone resistance. Growth Horm IGF Res 10(Suppl B):S9–S14CrossRef
26.
go back to reference Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN (2002) Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am J Physiol Endocrinol Metab 283:E472–E481PubMed Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN (2002) Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am J Physiol Endocrinol Metab 283:E472–E481PubMed
27.
go back to reference Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G, Mehls O (1998) Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 139:3296–3305PubMed Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G, Mehls O (1998) Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 139:3296–3305PubMed
28.
go back to reference Fernandez-Vojvodich P, Palmblad K, Karimian E, Andersson U, Savendahl L (2012) Pro-inflammatory cytokines produced by growth plate chondrocytes may act locally to modulate longitudinal bone growth. Horm Res Paediatr 77:180–187PubMedCrossRef Fernandez-Vojvodich P, Palmblad K, Karimian E, Andersson U, Savendahl L (2012) Pro-inflammatory cytokines produced by growth plate chondrocytes may act locally to modulate longitudinal bone growth. Horm Res Paediatr 77:180–187PubMedCrossRef
29.
go back to reference MacRae VE, Farquharson C, Ahmed SF (2006) The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 189:319–328PubMedCrossRef MacRae VE, Farquharson C, Ahmed SF (2006) The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 189:319–328PubMedCrossRef
30.
go back to reference De Benedetti F (2009) The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. Horm Res 72(Suppl 1):26–29PubMedCrossRef De Benedetti F (2009) The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. Horm Res 72(Suppl 1):26–29PubMedCrossRef
31.
go back to reference Fernandez-Vojvodich P, Karimian E, Savendahl L (2011) The biologics anakinra and etanercept prevent cytokine-induced growth retardation in cultured fetal rat metatarsal bones. Horm Res Paediatr 76:278–285PubMedCrossRef Fernandez-Vojvodich P, Karimian E, Savendahl L (2011) The biologics anakinra and etanercept prevent cytokine-induced growth retardation in cultured fetal rat metatarsal bones. Horm Res Paediatr 76:278–285PubMedCrossRef
32.
go back to reference Fernandez-Vojvodich P, Zaman F, Savendahl L (2013) Interleukin-6 acts locally on the growth plate to impair bone growth. Ann Rheum Dis 72:e24PubMedCrossRef Fernandez-Vojvodich P, Zaman F, Savendahl L (2013) Interleukin-6 acts locally on the growth plate to impair bone growth. Ann Rheum Dis 72:e24PubMedCrossRef
33.
go back to reference Martensson K, Chrysis D, Savendahl L (2004) Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 19:1805–1812PubMedCrossRef Martensson K, Chrysis D, Savendahl L (2004) Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 19:1805–1812PubMedCrossRef
34.
go back to reference Wong SC, MacRae VE, Gracie JA, McInnes IB, Galea P, Gardner-Medwin J, Ahmed SF (2008) Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res 18:369–378PubMedCrossRef Wong SC, MacRae VE, Gracie JA, McInnes IB, Galea P, Gardner-Medwin J, Ahmed SF (2008) Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res 18:369–378PubMedCrossRef
35.
go back to reference Schmeling H, Seliger E, Horneff G (2003) Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 21:779–784PubMed Schmeling H, Seliger E, Horneff G (2003) Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 21:779–784PubMed
36.
go back to reference Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW (2010) Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 62:3259–3264PubMedCrossRef Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW (2010) Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 62:3259–3264PubMedCrossRef
37.
go back to reference Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH (2010) Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology 49:1550–1558PubMedCrossRef Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH (2010) Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology 49:1550–1558PubMedCrossRef
38.
go back to reference De Benedetti F (2013) Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med 368:1256–1257PubMedCrossRef De Benedetti F (2013) Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med 368:1256–1257PubMedCrossRef
39.
go back to reference Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396–2406PubMedCrossRef Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396–2406PubMedCrossRef
40.
go back to reference Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70:747–754PubMedCrossRefPubMedCentral Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70:747–754PubMedCrossRefPubMedCentral
41.
go back to reference Svantesson H (1991) Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis: a pilot study. Clin Exp Rheumatol 9(Suppl 6):47–50PubMed Svantesson H (1991) Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis: a pilot study. Clin Exp Rheumatol 9(Suppl 6):47–50PubMed
42.
go back to reference Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM, Preece MA, Woo PM (1997) Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 40:332–340PubMedCrossRef Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM, Preece MA, Woo PM (1997) Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 40:332–340PubMedCrossRef
43.
go back to reference Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P (1998) Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 83:403–409PubMed Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P (1998) Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 83:403–409PubMed
44.
go back to reference Bechtold S, Ripperger P, Muhlbayer D, Truckenbrodt H, Hafner R, Butenandt O, Schwarz HP (2001) GH therapy in juvenile chronic arthritis: results of a 2-year controlled study on growth and bone. J Clin Endocrinol Metab 86:5737–5744PubMedCrossRef Bechtold S, Ripperger P, Muhlbayer D, Truckenbrodt H, Hafner R, Butenandt O, Schwarz HP (2001) GH therapy in juvenile chronic arthritis: results of a 2-year controlled study on growth and bone. J Clin Endocrinol Metab 86:5737–5744PubMedCrossRef
45.
go back to reference Bechtold S, Ripperger P, Hafner R, Said E, Schwarz HP (2003) Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 143:512–519PubMedCrossRef Bechtold S, Ripperger P, Hafner R, Said E, Schwarz HP (2003) Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 143:512–519PubMedCrossRef
46.
go back to reference Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P (2007) Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 92:2567–2573PubMedCrossRef Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P (2007) Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 92:2567–2573PubMedCrossRef
47.
go back to reference Hogler W, Shaw N (2010) Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol 72:281–289CrossRef Hogler W, Shaw N (2010) Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol 72:281–289CrossRef
48.
go back to reference Bechtold S, Ripperger P, Dalla Pozza R, Roth J, Hafner R, Michels H, Schwarz HP (2010) Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone. J Clin Endocrinol Metab 95:178–185PubMedCrossRef Bechtold S, Ripperger P, Dalla Pozza R, Roth J, Hafner R, Michels H, Schwarz HP (2010) Dynamics of body composition and bone in patients with juvenile idiopathic arthritis treated with growth hormone. J Clin Endocrinol Metab 95:178–185PubMedCrossRef
Metadata
Title
Growth abnormalities in children and adolescents with juvenile idiopathic arthritis
Authors
Susanne Bechtold
Dominique Simon
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 11/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3022-2

Other articles of this Issue 11/2014

Rheumatology International 11/2014 Go to the issue